UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI.
Yi-Chien HsiehTsung-Kun ChangWei-Chih SuChing-Wen HuangHsiang-Lin TsaiYen-Cheng ChenChing-Chun LiPo-Jung ChenTzu-Chieh YinCheng-Jen MaJaw-Yuan WangPublished in: Journal of oncology (2021)
The oncological outcomes of patients with BRAF-mutated mCRC treated using FOLFIRI plus bevacizumab with irinotecan dose escalation as a first-line therapy are acceptable with tolerable AEs; this may be a feasible treatment option in such patients. Pretherapeutic UGT1A1 genotyping-guided dose adjustment can achieve favorable outcomes.
Keyphrases
- metastatic colorectal cancer
- newly diagnosed
- end stage renal disease
- ejection fraction
- chronic kidney disease
- open label
- prognostic factors
- peritoneal dialysis
- stem cells
- randomized controlled trial
- rectal cancer
- gene expression
- skeletal muscle
- robot assisted
- radical prostatectomy
- combination therapy
- bone marrow
- mesenchymal stem cells
- study protocol
- glycemic control